Creative – CounterX Therapeutics

Home
About
Platform
Pipeline
- CTRX 101
- Publications
News
Team
Contact

Search Posts

Search

About Us

Lorem ipsum dolor sit amet, consectetur adipisc glelit, sed do eiusmod tempor incididunt .ut labo et dolore magna aliqua.

Blog Categories

Press Release (3)
Publications (9)

Recent Posts

CounterX Therapeutics Executes Exclusive Licensing Agreement for Portfolio of Novel Monoclonal Antibody and Vaccine Candidates Targeting Fentanyl and Opioid Overdose

CounterX Therapeutics Announces Formation of Scientific Advisory Board with Leading Experts in Substance Use Disorders

October 29, 2025

CounterX Therapeutics Announces Publication Demonstrating CTRX-101, an Anti-Fentanyl Monoclonal Antibody Therapy, Reverses Fentanyl-Induced Overdose in Preclinical Model

Post placeholder image

October 10, 2025

An anti-fentanyl monoclonal antibody reverses fentanyl-induced apnea in pigs

Post placeholder image

January 21, 2025

Psychopharmacology: A humanized monoclonal antibody attenuates fentanyl self-administration and reverses and prevents fentanyl-induced ventilatory depression in rhesus monkeys

Post placeholder image

October 7, 2024

ACS Omega: Structure-Based Engineering of Monoclonal Antibodies for Improved Binding to Counteract the Effects of Fentanyl and Carfentanil

Recent Comments

No comments to show.

Tags

Nothing Found

It seems we can’t find what you’re looking for. Perhaps searching can help.

Follow Us
Contact Us

©2025 CounterX Therapeutics. All Rights Reserved.